Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 10, 2016 03:30 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Presents Interim Phase 1 Results for ACH-4471, a Novel Orally-Administered Factor D Inhibitor, at the 21st Congress of the European Hematology Association

- Results indicate up to 100% inhibition of alternative-pathway (AP) activity in hemolysis and Wieslab assays after oral dosing of ACH-4471 - - Results support initiation...
June 01, 2016 16:02 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion to Present at Three Upcoming Investor Conferences

NEW HAVEN, Conn., June 01, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion,...
May 19, 2016 06:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Announces Acceptance of Late Breaking Abstract for ACH-4471 at the 21st Congress of the European Hematology Association

- Interim results, including safety, pharmacokinetics and pharmacodynamics, to be presented from ongoing phase 1 single-ascending dose trial with ACH-4471 in healthy volunteers - NEW HAVEN,...
May 03, 2016 06:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Reports First Quarter 2016 Financial Results and Provides Update on Clinical Programs

- Company provides update on HCV collaboration with Janssen; Phase 2b combination study evaluating doublet and triplet regimens for six and eight weeks anticipated to begin in Q3 2016 – ...
April 28, 2016 06:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion to Present at the Deutsche Bank 41st Annual Health Care Conference

NEW HAVEN, Conn., April 28, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion,...
March 03, 2016 06:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion to Present at Two Upcoming Investor Conferences

NEW HAVEN, Conn., March 03, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion,...
February 25, 2016 06:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Reports 2015 Fourth Quarter and Year-End Financial Results

NEW HAVEN, Conn., Feb. 25, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three and twelve month periods ending December 31, 2015. ...
February 11, 2016 06:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Initiates Phase 1 Study of ACH-4471, First Orally-Administered Small Molecule Complement Factor D Inhibitor

NEW HAVEN, Conn., Feb. 11, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the initiation of a phase 1 study with ACH-4471, the Company’s first...
February 08, 2016 16:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion to Present at the Leerink Partners 5th Annual Global Healthcare Conference

NEW HAVEN, Conn., Feb. 08, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion,...
February 03, 2016 06:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Announces Appointments of Martha Manning as General Counsel and Amy Jennings as Head of Regulatory Affairs

NEW HAVEN, Conn., Feb. 03, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the addition of two members to the senior management team. Martha Manning, Esq.,...